1. Abiko LA, Grahl A, Grzesiek S. (2019) High Pressure Shifts the β1-Adrenergic Receptor to the Active Conformation in the Absence of G Protein. J Am Chem Soc, 141 (42): 16663-16670. [PMID:31564099]
2. Adkins JC, Balfour JA. (1998) Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging, 12 (3): 225-41. [PMID:9534022]
3. Ahlquist RP. (1948) A study of the adrenotropic receptors. Am J Physiol, 153 (3): 586-600.
4. Akinaga J, García-Sáinz JA, S Pupo A. (2019) Updates in the function and regulation of α1 -adrenoceptors. Br J Pharmacol, 176 (14): 2343-2357. [PMID:30740663]
5. Alegre KO, Paknejad N, Su M, Lou JS, Huang J, Jordan KD, Eng ET, Meyerson JR, Hite RK, Huang XY. (2021) Structural basis and mechanism of activation of two different families of G proteins by the same GPCR. Nat Struct Mol Biol, 28 (11): 936-944. [PMID:34759376]
6. Arch JR. (2011) Challenges in β(3)-Adrenoceptor Agonist Drug Development. Ther Adv Endocrinol Metab, 2 (2): 59-64. [PMID:23148171]
7. Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S. (1984) Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature, 309 (5964): 163-5. [PMID:6325935]
8. Baker JG. (2005) Evidence for a secondary state of the human beta3-adrenoceptor. Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733]
9. Baker JG. (2005) Site of action of beta-ligands at the human beta1-adrenoceptor. J Pharmacol Exp Ther, 313 (3): 1163-71. [PMID:15716385]
10. Baker JG. (2005) The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol, 144 (3): 317-22. [PMID:15655528]
11. Baker JG. (2010) The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol, 160 (5): 1048-61. [PMID:20590599]
12. Baker JG, Gardiner SM, Woolard J, Fromont C, Jadhav GP, Mistry SN, Thompson KSJ, Kellam B, Hill SJ, Fischer PM. (2017) Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. FASEB J, 31 (7): 3150-3166. [PMID:28400472]
13. Baker JG, Hall IP, Hill SJ. (2003) Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor. Mol Pharmacol, 63 (6): 1312-21. [PMID:12761341]
14. Baker JG, Proudman RG, Hill SJ. (2014) Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor. Mol Pharmacol, 85 (5): 811-29. [PMID:24608857]
15. Barends CR, Absalom A, van Minnen B, Vissink A, Visser A. (2017) Dexmedetomidine versus Midazolam in Procedural Sedation. A Systematic Review of Efficacy and Safety. PLoS One, 12 (1): e0169525. [PMID:28107373]
16. Battaglia G, Shannon M, Borgundvaag B, Titeler M. (1983) Properties of [3H]prazosin-labeled alpha 1-adrenergic receptors in rat brain and porcine neurointermediate lobe tissue. J Neurochem, 41 (2): 538-42. [PMID:6308163]
17. Benkel T, Zimmermann M, Zeiner J, Bravo S, Merten N, Lim VJY, Matthees ESF, Drube J, Miess-Tanneberg E, Malan D et al.. (2022) How Carvedilol activates β2-adrenoceptors. Nat Commun, 13 (1): 7109. [PMID:36402762]
18. Berthelsen S, Pettinger WA. (1977) A functional basis for classification of alpha-adrenergic receptors. Life Sci, 21 (5): 595-606. [PMID:20542]
19. Billington CK, Penn RB, Hall IP. (2017) β2 Agonists. Handb Exp Pharmacol, 237: 23-40. [PMID:27878470]
20. Blaxall HS, Murphy TJ, Baker JC, Ray C, Bylund DB. (1991) Characterization of the alpha-2C adrenergic receptor subtype in the opossum kidney and in the OK cell line. J Pharmacol Exp Ther, 259 (1): 323-9. [PMID:1656026]
21. Blin N, Camoin L, Maigret B, Strosberg AD. (1993) Structural and conformational features determining selective signal transduction in the beta 3-adrenergic receptor. Mol Pharmacol, 44 (6): 1094-104. [PMID:7903415]
22. Blin N, Nahmias C, Drumare MF, Strosberg AD. (1994) Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor. Br J Pharmacol, 112 (3): 911-9. [PMID:7921620]
23. Bond RA, Clarke DE. (1988) Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the alpha- and beta-subtypes. Br J Pharmacol, 95: 723-734. [PMID:2905184]
24. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S et al.. (1986) Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res, 59 (3): 297-309. [PMID:2876788]
25. Bullowa J, Kaplan D. (1903) Treatment of asthmatic attacks: on the hypodermatic use of adrenalin chloride in the treatment of asthmatic attacks. Med News, 83: 787-90.
26. Burnett J. (1903) Adrenalin: a short account of its therapeutic applications. The Medical Times and Hospital Gazette, June 20: 385-7.
27. Bylund DB. (1988) Subtypes of alpha 2-adrenoceptors: pharmacological and molecular biological evidence converge. Trends Pharmacol Sci, 9 (10): 356-61. [PMID:2855960]
28. Bylund DB. (2005) Alpha-2 adrenoceptor subtypes: are more better?. Br J Pharmacol, 144 (2): 159-60. [PMID:15655520]
29. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo Jr RR, Trendelenburg U. (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev, 46 (2): 121-36. [PMID:7938162]
30. Bylund DB, Ray-Prenger C, Murphy TJ. (1988) Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther, 245 (2): 600-7. [PMID:2835476]
31. Catus SL, Gibbs ME, Sato M, Summers RJ, Hutchinson DS. (2011) Role of β-adrenoceptors in glucose uptake in astrocytes using β-adrenoceptor knockout mice. Br J Pharmacol, 162 (8): 1700-15. [PMID:21138422]
32. Chang DJ, Chang TK, Yamanishi SS, Salazar FH, Kosaka AH, Khare R, Bhakta S, Jasper JR, Shieh IS, Lesnick JD et al.. (1998) Molecular cloning, genomic characterization and expression of novel human alpha1A-adrenoceptor isoforms. FEBS Lett, 422 (2): 279-83. [PMID:9490024]
33. Chen X, Xu Y, Qu L, Wu L, Han GW, Guo Y, Wu Y, Zhou Q, Sun Q, Chu C et al.. (2019) Molecular Mechanism for Ligand Recognition and Subtype Selectivity of α2C Adrenergic Receptor. Cell Rep, 29 (10): 2936-2943.e4. [PMID:31801061]
34. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK et al.. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science, 318 (5854): 1258-65. [PMID:17962520]
35. Chung FZ, Lentes KU, Gocayne J, Fitzgerald M, Robinson D, Kerlavage AR, Fraser CM, Venter JC. (1987) Cloning and sequence analysis of the human brain beta-adrenergic receptor. Evolutionary relationship to rodent and avian beta-receptors and porcine muscarinic receptors. FEBS Lett, 211 (2): 200-6. [PMID:3026848]
36. Collins S. (2011) β-Adrenoceptor Signaling Networks in Adipocytes for Recruiting Stored Fat and Energy Expenditure. Front Endocrinol (Lausanne), 2: 102. [PMID:22654837]
37. Cotecchia S, Schwinn DA, Randall RR, Lefkowitz RJ, Caron MG, Kobilka BK. (1988) Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor. Proc Natl Acad Sci USA, 85 (19): 7159-63. [PMID:2845398]
38. Cruickshank JM. (1993) The xamoterol experience in the treatment of heart failure. Am J Cardiol, 71 (9): 61C-64C. [PMID:8465800]
39. da Silva Junior ED, Sato M, Merlin J, Broxton N, Hutchinson DS, Ventura S, Evans BA, Summers RJ. (2017) Factors influencing biased agonism in recombinant cells expressing the human α1A -adrenoceptor. Br J Pharmacol, 174 (14): 2318-2333. [PMID:28444738]
40. Dale HH. (1906) On some physiological actions of ergot. Am J Physiol, 34 (3): 163-206.
41. Dehvari N, Sato M, Bokhari MH, Kalinovich A, Ham S, Gao J, Nguyen HTM, Whiting L, Mukaida S, Merlin J et al.. (2020) The metabolic effects of mirabegron are mediated primarily by β3 -adrenoceptors. Pharmacol Res Perspect, 8 (5): e00643. [PMID:32813332]
42. Deluigi M, Morstein L, Schuster M, Klenk C, Merklinger L, Cridge RR, de Zhang LA, Klipp A, Vacca S, Vaid TM et al.. (2022) Crystal structure of the α1B-adrenergic receptor reveals molecular determinants of selective ligand recognition. Nat Commun, 13 (1): 382. [PMID:35046410]
43. DeVree BT, Mahoney JP, Vélez-Ruiz GA, Rasmussen SG, Kuszak AJ, Edwald E, Fung JJ, Manglik A, Masureel M, Du Y et al.. (2016) Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. Nature, 535 (7610): 182-6. [PMID:27362234]
44. Diamanti E, Del Bello F, Carbonara G, Carrieri A, Fracchiolla G, Giannella M, Mammoli V, Piergentili A, Pohjanoksa K, Quaglia W et al.. (2012) Might the observed α(2A)-adrenoreceptor agonism or antagonism of allyphenyline analogues be ascribed to different molecular conformations?. Bioorg Med Chem, 20 (6): 2082-90. [PMID:22341244]
45. Dixon RA, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, Frielle T, Bolanowski MA, Bennett CD, Rands E, Diehl RE et al.. (1986) Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature, 321 (6065): 75-9. [PMID:3010132]
46. Eason MG, Kurose H, Holt BD, Raymond JR, Liggett SB. (1992) Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs. J Biol Chem, 267 (22): 15795-801. [PMID:1322406]
47. Eason MG, Liggett SB. (1993) Human alpha 2-adrenergic receptor subtype distribution: widespread and subtype-selective expression of alpha 2C10, alpha 2C4, and alpha 2C2 mRNA in multiple tissues. Mol Pharmacol, 44 (1): 70-5. [PMID:7688069]
48. Eason MG, Liggett SB. (1995) Identification of a Gs coupling domain in the amino terminus of the third intracellular loop of the alpha 2A-adrenergic receptor. Evidence for distinct structural determinants that confer Gs versus Gi coupling. J Biol Chem, 270 (42): 24753-60. [PMID:7559592]
49. Elnatan J, Molenaar P, Rosenfeldt FL, Summers RJ. (1994) Autoradiographic localization and quantitation of beta 1- and beta 2-adrenoceptors in the human atrioventricular conducting system: a comparison of patients with idiopathic dilated cardiomyopathy and ischemic heart disease. J Mol Cell Cardiol, 26 (3): 313-23. [PMID:7913135]
50. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD. (1989) Molecular characterization of the human beta 3-adrenergic receptor. Science, 245 (4922): 1118-21. [PMID:2570461]
51. Erdozain AM, Brocos-Mosquera I, Gabilondo AM, Meana JJ, Callado LF. (2019) Differential α2A- and α2C-adrenoceptor protein expression in presynaptic and postsynaptic density fractions of postmortem human prefrontal cortex. J Psychopharmacol, 33 (2): 244-249. [PMID:30255728]
52. Evans BA, Broxton N, Merlin J, Sato M, Hutchinson DS, Christopoulos A, Summers RJ. (2011) Quantification of functional selectivity at the human α(1A)-adrenoceptor. Mol Pharmacol, 79 (2): 298-307. [PMID:20978120]
53. Evans BA, Papaioannou M, Hamilton S, Summers RJ. (1999) Alternative splicing generates two isoforms of the beta-3 adrenoceptor which are differentially expressed in mouse tissues. Br J Pharmacol, 127: 1525-1531. [PMID:10455305]
54. Fargin A, Raymond SR, Lohse MJ, Kobilka BK, Caron MG, Lefkowitz RJ. (1988) The genomic clone G-21 which resembles aβ-adrenergic receptor sequence encodes the 5-HT1Areceptor. Nature, 335: 358-360. [PMID:3138543]
55. Ford AP, Arredondo NF, Blue Jr DR, Bonhaus DW, Jasper J, Kava MS, Lesnick J, Pfister JR, Shieh IA, Vimont RL et al.. (1996) RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol, 49 (2): 209-15. [PMID:8632751]
56. Ford AP, Daniels DV, Chang DJ, Gever JR, Jasper JR, Lesnick JD, Clarke DE. (1997) Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification. Br J Pharmacol, 121 (6): 1127-35. [PMID:9249248]
57. Ford AP, Williams TJ, Blue DR, Clarke DE. (1994) Alpha 1-adrenoceptor classification: sharpening Occam's razor. Trends Pharmacol Sci, 15 (6): 167-70. [PMID:7916507]
58. Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamäki A. (2001) Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem, 276 (33): 31279-84. [PMID:11395517]
59. Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, Kobilka BK. (1987) Cloning of the cDNA for the human β1-adrenergic receptor. Proc Natl Acad Sci USA, 84: 7920-7924. [PMID:2825170]
60. Gaertner J, Fusi-Schmidhauser T. (2022) Dexmedetomidine: a magic bullet on its way into palliative care-a narrative review and practice recommendations. Ann Palliat Med, 11 (4): 1491-1504. [PMID:35400162]
61. Galitzky J, Langin D, Verwaerde P, Montastruc JL, Lafontan M, Berlan M. (1997) Lipolytic effects of conventional beta 3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative beta 4-adrenoceptor. Br J Pharmacol, 122 (6): 1244-50. [PMID:9401793]
62. Gibbs ME, Summers RJ. (2005) Contrasting roles for beta1, beta2 and beta3-adrenoceptors in memory formation in the chick. Neuroscience, 131 (1): 31-42. [PMID:15680689]
63. Giovannitti Jr JA, Thoms SM, Crawford JJ. (2015) Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog, 62 (1): 31-9. [PMID:25849473]
64. Graham RM, Perez DM, Hwa J, Piascik MT. (1996) alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signaling. Circ Res, 78 (5): 737-49. [PMID:8620593]
65. Granneman JG. (2001) The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor. Am J Physiol Endocrinol Metab, 280 (2): E199-202. [PMID:11158920]
66. Gray K, Short J, Ventura S. (2008) The alpha1A-adrenoceptor gene is required for the alpha1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate. Br J Pharmacol, 155 (1): 103-9. [PMID:18552869]
67. Hadi T, Barrichon M, Mourtialon P, Wendremaire M, Garrido C, Sagot P, Bardou M, Lirussi F. (2013) Biphasic Erk1/2 activation sequentially involving Gs and Gi signaling is required in beta3-adrenergic receptor-induced primary smooth muscle cell proliferation. Biochim Biophys Acta, 1833 (5): 1041-51. [PMID:23388888]
68. Han C, Abel PW, Minneman KP. (1987) Heterogeneity of alpha 1-adrenergic receptors revealed by chlorethylclonidine. Mol Pharmacol, 32 (4): 505-10. [PMID:2890094]
69. Hein P, Michel MC. (2007) Signal transduction and regulation: are all alpha1-adrenergic receptor subtypes created equal?. Biochem Pharmacol, 73 (8): 1097-106. [PMID:17141737]
70. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, Minneman KP, Ruffolo Jr RR. (1995) International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev, 47 (2): 267-70. [PMID:7568329]
71. Hirasawa A, Shibata K, Horie K, Takei Y, Obika K, Tanaka T, Muramoto N, Takagaki K, Yano J, Tsujimoto G. (1995) Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants. FEBS Lett, 363 (3): 256-60. [PMID:7737411]
72. Huang J, Chen S, Zhang JJ, Huang XY. (2013) Crystal structure of oligomeric β1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat Struct Mol Biol, 20 (4): 419-25. [PMID:23435379]
73. Igawa Y, Michel MC. (2013) Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol, 386 (3): 177-83. [PMID:23263450]
74. Jasper JR, Lesnick JD, Chang LK, Yamanishi SS, Chang TK, Hsu SA, Daunt DA, Bonhaus DW, Eglen RM. (1998) Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. Biochem Pharmacol, 55 (7): 1035-43. [PMID:9605427]
75. Johnson RD, Minneman KP. (1987) Differentiation of α1-adrenergic receptors linked to phosphatidylinositol turnover and cyclic AMP accumulation in rat brain. Mol Pharmacol, 31: 239-246. [PMID:2436033]
76. Kalinovich A, Dehvari N, Åslund A, van Beek S, Halleskog C, Olsen J, Forsberg E, Zacharewicz E, Schaart G, Rinde M et al.. (2020) Treatment with a β-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity. Diabetologia, 63 (8): 1603-1615. [PMID:32472192]
77. Kaumann AJ. (1997) Four beta-adrenoceptor subtypes in the mammalian heart. Trends Pharmacol Sci, 18 (3): 70-6. [PMID:9133774]
78. Kaumann AJ, Molenaar P. (1997) Modulation of human cardiac function through 4 beta-adrenoceptor populations. Naunyn Schmiedebergs Arch Pharmacol, 355 (6): 667-81. [PMID:9205950]
79. Kaumann AJ, Molenaar P. (2008) The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology. Pharmacol Ther, 118 (3): 303-36. [PMID:18501968]
80. Kaumann AJ, Preitner F, Sarsero D, Molenaar P, Revelli JP, Giacobino JP. (1998) (-)-CGP 12177 causes cardiostimulation and binds to cardiac putative beta 4-adrenoceptors in both wild-type and beta 3-adrenoceptor knockout mice. Mol Pharmacol, 53 (4): 670-5. [PMID:9547357]
81. Kenny BA, Chalmers DH, Philpott PC, Naylor AM. (1995) Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacol, 115 (6): 981-6. [PMID:7582530]
82. Kobilka BK, Dixon RA, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ. (1987) cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA, 84 (1): 46-50. [PMID:3025863]
83. Kobilka BK, Frielle T, Collins S, Yang-Feng T, Kobilka TS, Francke U, Lefkowitz RJ, Caron MG. (1987) An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature, 329 (6134): 75-9. [PMID:3041227]
84. Kobilka BK, Matsui H, Kobilka TS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ, Regan JW. (1987) Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor. Science, 238 (4827): 650-6. [PMID:2823383]
85. Konkar AA, Zhu Z, Granneman JG. (2000) Aryloxypropanolamine and catecholamine ligand interactions with the beta(1)-adrenergic receptor: evidence for interaction with distinct conformations of beta(1)-adrenergic receptors. J Pharmacol Exp Ther, 294 (3): 923-32. [PMID:10945842]
86. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown Jr TG. (1967) Differentiation of receptor systems activated by sympathomimetic amines. Nature, 214 (5088): 597-8. [PMID:6036174]
87. Langer SZ. (2015) α2-Adrenoceptors in the treatment of major neuropsychiatric disorders. Trends Pharmacol Sci, 36 (4): 196-202. [PMID:25771972]
88. Lanier SM, Downing S, Duzic E, Homcy CJ. (1991) Isolation of rat genomic clones encoding subtypes of the alpha 2-adrenergic receptor. Identification of a unique receptor subtype. J Biol Chem, 266 (16): 10470-8. [PMID:1645350]
89. Lee S. (2019) Dexmedetomidine: present and future directions. Korean J Anesthesiol, 72 (4): 323-330. [PMID:31220910]
90. Lehto J, Hirvonen MM, Johansson J, Kemppainen J, Luoto P, Naukkarinen T, Oikonen V, Arponen E, Rouru J, Sallinen J et al.. (2015) Validation of [(11) C]ORM-13070 as a PET tracer for alpha2c -adrenoceptors in the human brain. Synapse, 69 (3): 172-81. [PMID:25530024]
91. Leslie AG, Warne T, Tate CG. (2015) Ligand occupancy in crystal structure of β1-adrenergic G protein-coupled receptor. Nat Struct Mol Biol, 22 (12): 941-2. [PMID:26643842]
92. Limbird LE. (1988) Receptors linked to inhibition of adenylate cyclase: additional signaling mechanisms. FASEB J, 2 (11): 2686-95. [PMID:2840317]
93. Liu X, Ahn S, Kahsai AW, Meng KC, Latorraca NR, Pani B, Venkatakrishnan AJ, Masoudi A, Weis WI, Dror RO et al.. (2017) Mechanism of intracellular allosteric β2AR antagonist revealed by X-ray crystal structure. Nature, 548 (7668): 480-484. [PMID:28813418]
94. Lomasney JW, Cotecchia S, Lorenz W, Leung WY, Schwinn DA, Yang-Feng TL, Brownstein M, Lefkowitz RJ, Caron MG. (1991) Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5. J Biol Chem, 266 (10): 6365-9. [PMID:1706716]
95. MacDonald E, Kobilka BK, Scheinin M. (1997) Gene targeting--homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci, 18 (6): 211-9. [PMID:9227000]
96. Manglik A, Kim TH, Masureel M, Altenbach C, Yang Z, Hilger D, Lerch MT, Kobilka TS, Thian FS, Hubbell WL et al.. (2015) Structural Insights into the Dynamic Process of β2-Adrenergic Receptor Signaling. Cell, 161 (5): 1101-11. [PMID:25981665]
97. Masureel M, Zou Y, Picard LP, van der Westhuizen E, Mahoney JP, Rodrigues JPGLM, Mildorf TJ, Dror RO, Shaw DE, Bouvier M et al.. (2018) Structural insights into binding specificity, efficacy and bias of a β2AR partial agonist. Nat Chem Biol, 14 (11): 1059-1066. [PMID:30327561]
98. Michel AD, Loury DN, Whiting RL. (1989) Differences between the alpha 2-adrenoceptor in rat submaxillary gland and the alpha 2A-and alpha 2B-adrenoceptor subtypes. Br J Pharmacol, 98 (3): 890-7. [PMID:2556205]
99. Michel MC, Korstanje C. (2016) β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project. Pharmacol Ther, 159: 66-82. [PMID:26808167]
100. Michel MC, Seifert R. (2015) Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms. Am J Physiol, Cell Physiol, 308 (7): C505-20. [PMID:25631871]
101. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther, 303 (2): 791-804. [PMID:12388666]
102. Miller-Gallacher JL, Nehmé R, Warne T, Edwards PC, Schertler GF, Leslie AG, Tate CG. (2014) The 2.1 Å resolution structure of cyanopindolol-bound β1-adrenoceptor identifies an intramembrane Na+ ion that stabilises the ligand-free receptor. PLoS One, 9 (3): e92727. [PMID:24663151]
103. Minneman KP. (1988) Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+. Pharmacol Rev, 40 (2): 87-119. [PMID:2853370]
104. Minneman KP, Han C, Abel PW. (1988) Comparison of α1-adrenergic receptor subtypes distinguished by chloroethylclonidine and WB4101. Mol Pharmacol, 33: 509-514. [PMID:2835650]
105. Morrow AL, Creese I. (1986) Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding. Mol Pharmacol, 29 (4): 321-30. [PMID:3010073]
106. Muramatsu I, Oshita M, Ohmura T, Kigoshi S, Akino H, Gobara M, Okada K. (1994) Pharmacological characterization of alpha 1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br J Urol, 74 (5): 572-8. [PMID:7530120]
107. Murphy TJ, Bylund DB. (1988) Characterization of alpha-2 adrenergic receptors in the OK cell, an opossum kidney cell line. J Pharmacol Exp Ther, 244 (2): 571-8. [PMID:2894455]
108. Méjean A, Guillaume JL, Strosberg AD. (1995) Carazolol: a potent, selective beta 3-adrenoceptor agonist. Eur J Pharmacol, 291 (3): 359-66. [PMID:8719421]
109. Nagiri C, Kobayashi K, Tomita A, Kato M, Kobayashi K, Yamashita K, Nishizawa T, Inoue A, Shihoya W, Nureki O. (2021) Cryo-EM structure of the β3-adrenergic receptor reveals the molecular basis of subtype selectivity. Mol Cell, 81 (15): 3205-3215.e5. [PMID:34314699]
110. Newcorn JH, Krone B, Dittmann RW. (2022) Nonstimulant Treatments for ADHD. Child Adolesc Psychiatr Clin N Am, 31 (3): 417-435. [PMID:35697393]
111. O'Connell TD, Jensen BC, Baker AJ, Simpson PC. (2014) Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. Pharmacol Rev, 66 (1): 308-33. [PMID:24368739]
112. Okeke K, Angers S, Bouvier M, Michel MC. (2019) Agonist-induced desensitisation of β3 -adrenoceptors: Where, when, and how?. Br J Pharmacol, 176 (14): 2539-2558. [PMID:30809805]
113. Okwundu N, Cline A, Feldman SR. (2021) Difference in vasoconstrictors: oxymetazoline vs. brimonidine. J Dermatolog Treat, 32 (2): 137-143. [PMID:31294643]
114. Oliver G, Schäfer EA. (1894) On the physiological action of extracts of the suprarenal capsule. J Physiol, 16: 1-4.
115. Oliver G, Schäfer EA. (1895) On the Physiological Action of Extracts of Pituitary Body and certain other Glandular Organs: Preliminary Communication. J Physiol (Lond.), 18 (3): 277-9. [PMID:16992253]
116. Oshita M, Kigoshi S, Muramatsu I. (1991) Three distinct binding sites for [3H]-prazosin in the rat cerebral cortex. Br J Pharmacol, 104 (4): 961-5. [PMID:1687370]
117. Pak MD, Fishman PH. (1996) Anomalous behavior of CGP 12177A on beta 1-adrenergic receptors. J Recept Signal Transduct Res, 16 (1-2): 1-23. [PMID:8771528]
118. Pandey S, Saha S, Shukla AK. (2020) Transmitting the Signal: Structure of the β1-Adrenergic Receptor-Gs Protein Complex. Mol Cell, 80 (1): 3-5. [PMID:33007256]
119. Peltonen JM, Pihlavisto M, Scheinin M. (1998) Subtype-specific stimulation of [35S]GTPgammaS binding by recombinant alpha2-adrenoceptors. Eur J Pharmacol, 355 (2-3): 275-9. [PMID:9760042]
120. Perez DM, Piascik MT, Graham RM. (1991) Solution-phase library screening for the identification of rare clones: isolation of an alpha 1D-adrenergic receptor cDNA. Mol Pharmacol, 40 (6): 876-83. [PMID:1661838]
121. Perälä M, Hirvonen H, Kalimo H, Ala-Uotila S, Regan JW, Akerman KE, Scheinin M. (1992) Differential expression of two alpha 2-adrenergic receptor subtype mRNAs in human tissues. Brain Res Mol Brain Res, 16 (1-2): 57-63. [PMID:1334200]
122. Piascik MT, Guarino RD, Smith MS, Soltis EE, Saussy Jr DL, Perez DM. (1995) The specific contribution of the novel alpha-1D adrenoceptor to the contraction of vascular smooth muscle. J Pharmacol Exp Ther, 275 (3): 1583-9. [PMID:8531132]
123. Piascik MT, Perez DM. (2001) Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther, 298 (2): 403-10. [PMID:11454900]
124. Pihlavisto M, Sjöholm B, Scheinin M, Wurster S. (1998) Modulation of agonist binding to recombinant human alpha2-adrenoceptors by sodium ions. Biochim Biophys Acta, 1448 (1): 135-46. [PMID:9824686]
125. Piwnica D, Rosignoli C, de Ménonville ST, Alvarez T, Schuppli Nollet M, Roye O, Jomard A, Aubert J. (2014) Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. J Dermatol Sci, 75 (1): 49-54. [PMID:24802713]
126. Proudman RGW, Akinaga J, Baker JG. (2022) The affinity and selectivity of α-adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors. Pharmacol Res Perspect, 10 (2): e00936. [PMID:35224877]
127. Proudman RGW, Akinaga J, Baker JG. (2022) The signaling and selectivity of α-adrenoceptor agonists for the human α2A, α2B and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors. Pharmacol Res Perspect, 10 (5): e01003. [PMID:36101495]
128. Proudman RGW, Baker JG. (2021) The selectivity of α-adrenoceptor agonists for the human α1A, α1B, and α1D-adrenoceptors. Pharmacol Res Perspect, 9 (4): e00799. [PMID:34355529]
129. Proudman RGW, Pupo AS, Baker JG. (2020) The affinity and selectivity of α-adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D-adrenoceptors. Pharmacol Res Perspect, 8 (4): e00602. [PMID:32608144]
130. Qu L, Zhou Q, Xu Y, Guo Y, Chen X, Yao D, Han GW, Liu ZJ, Stevens RC, Zhong G et al.. (2019) Structural Basis of the Diversity of Adrenergic Receptors. Cell Rep, 29 (10): 2929-2935.e4. [PMID:31801060]
131. Regan JW, Kobilka TS, Yang-Feng TL, Caron MG, Lefkowitz RJ, Kobilka BK. (1988) Cloning and expression of a human kidney cDNA for an alpha 2-adrenergic receptor subtype. Proc Natl Acad Sci USA, 85 (17): 6301-5. [PMID:2842764]
132. Ring AM, Manglik A, Kruse AC, Enos MD, Weis WI, Garcia KC, Kobilka BK. (2013) Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Nature, 502 (7472): 575-579. [PMID:24056936]
133. Roberts SJ, Papaioannou M, Evans BA, Summers RJ. (1997) Functional and molecular evidence for beta 1-, beta 2- and beta 3- adrenoceptors in human colon. Br J Pharmacol, 120 (8): 1527-35. [PMID:9113375]
134. Ruuskanen JO, Xhaard H, Marjamäki A, Salaneck E, Salminen T, Yan YL, Postlethwait JH, Johnson MS, Larhammar D, Scheinin M. (2004) Identification of duplicated fourth alpha2-adrenergic receptor subtype by cloning and mapping of five receptor genes in zebrafish. Mol Biol Evol, 21 (1): 14-28. [PMID:12949138]
135. Sarsero D, Molenaar P, Kaumann AJ. (1998) Validity of (-)-[3H]-CGP 12177A as a radioligand for the 'putative beta4-adrenoceptor' in rat atrium. Br J Pharmacol, 123 (3): 371-80. [PMID:9504376]
136. Sato M, Dehvari N, Oberg AI, Dallner OS, Sandström AL, Olsen JM, Csikasz RI, Summers RJ, Hutchinson DS, Bengtsson T. (2014) Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes, 63 (12): 4115-29. [PMID:25008179]
137. Sato M, Horinouchi T, Hutchinson DS, Evans BA, Summers RJ. (2007) Ligand-directed signaling at the beta3-adrenoceptor produced by 3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) relative to receptor agonists. Mol Pharmacol, 72 (5): 1359-68. [PMID:17717109]
138. Sato M, Hutchinson DS, Evans BA, Summers RJ. (2008) The beta3-adrenoceptor agonist 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-benzenesulfonamide (L755507) and antagonist (S)-N-[4-[2-[[3-[3-(acetamidomethyl)phenoxy]-2-hydroxypropyl]amino]-ethyl]phenyl]benzenesulfonamide (L748337) activate different signaling pathways in Chinese hamster ovary-K1 cells stably expressing the human beta3-adrenoceptor. Mol Pharmacol, 74 (5): 1417-28. [PMID:18684840]
139. Sato T, Baker J, Warne T, Brown GA, Leslie AG, Congreve M, Tate CG. (2015) Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound β1-Adrenergic Receptor. Mol Pharmacol, 88 (6): 1024-34. [PMID:26385885]
140. Schena G, Caplan MJ. (2019) Everything You Always Wanted to Know about β3-AR * (* But Were Afraid to Ask). Cells, 8 (4). [PMID:30995798]
141. Schmidt M, Dekker FJ, Maarsingh H. (2013) Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regulation of diverse biological functions. Pharmacol Rev, 65 (2): 670-709. [PMID:23447132]
142. Schwinn DA, Lomasney JW, Lorenz W, Szklut PJ, Fremeau Jr RT, Yang-Feng TL, Caron MG, Lefkowitz RJ, Cotecchia S. (1990) Molecular cloning and expression of the cDNA for a novel alpha 1-adrenergic receptor subtype. J Biol Chem, 265 (14): 8183-9. [PMID:1970822]
143. Severi C, Tattoli I, Romano G, Corleto VD, Delle Fave G. (2004) Beta3-adrenoceptors: relaxant function and mRNA detection in smooth muscle cells isolated from the human colon. Can J Physiol Pharmacol, 82 (7): 515-22. [PMID:15389299]
144. Simonneaux V, Ebadi M, Bylund DB. (1991) Identification and characterization of alpha 2D-adrenergic receptors in bovine pineal gland. Mol Pharmacol, 40 (2): 235-41. [PMID:1652052]
145. Strosberg AD. (1997) Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol, 37: 421-50. [PMID:9131260]
146. Su M, Zhu L, Zhang Y, Paknejad N, Dey R, Huang J, Lee MY, Williams D, Jordan KD, Eng ET et al.. (2020) Structural Basis of the Activation of Heterotrimeric Gs-Protein by Isoproterenol-Bound β1-Adrenergic Receptor. Mol Cell, 80 (1): 59-71.e4. [PMID:32818430]
147. Summers RJ, Molenaar P, Stephenson JA. (1987) Autoradiographic localization of receptors in the cardiovascular system. TiPS, 8 (7): 272-276. DOI: 10.1016/0165-6147(87)90202-1
148. Summers RJ, Molnaar P, Russell F, Elnatan J, Jones CR, Buxton BF, Chang V, Hambley J. (1989) Coexistence and localization of beta 1- and beta 2-adrenoceptors in the human heart. Eur Heart J, 10 Suppl B: 11-21. [PMID:2553407]
149. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A et al.. (2015) Proteomics. Tissue-based map of the human proteome. Science, 347 (6220): 1260419. [PMID:25613900]
150. Ul-Haq Z, Saeed M, Halim SA, Khan W. (2015) 3D structure prediction of human β1-adrenergic receptor via threading-based homology modeling for implications in structure-based drug designing. PLoS One, 10 (4): e0122223. [PMID:25860348]
151. Urits I, Patel A, Zusman R, Virgen CG, Mousa M, Berger AA, Kassem H, Jung JW, Hasoon J, Kaye AD et al.. (2020) A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms. Psychopharmacol Bull, 50 (3): 76-96. [PMID:32733113]
152. van Wieringen JP, Michel-Reher MB, Hatanaka T, Ueshima K, Michel MC. (2013) The new radioligand [(3)H]-L 748,337 differentially labels human and rat β3-adrenoceptors. Eur J Pharmacol, 720 (1-3): 124-30. [PMID:24183974]
153. Walter M, Lemoine H, Kaumann AJ. (1984) Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig. Role of beta-adrenoceptor subtypes in the dissociation between blockade and stimulation. Naunyn Schmiedebergs Arch Pharmacol, 327 (2): 159-75. [PMID:6092972]
154. Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. (2017) Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clin Pharmacokinet, 56 (8): 893-913. [PMID:28105598]
155. Weichert D, Kruse AC, Manglik A, Hiller C, Zhang C, Hübner H, Kobilka BK, Gmeiner P. (2014) Covalent agonists for studying G protein-coupled receptor activation. Proc Natl Acad Sci U S A, 111 (29): 10744-8. [PMID:25006259]
156. Weinshank RL, Zgombick JM, Macchi M, Adham N, Lichtblau H, Branchek TA, Hartig PR. (1990) Cloning, expression, and pharmacological characterization of a human alpha 2B-adrenergic receptor. Mol Pharmacol, 38 (5): 681-8. [PMID:2172775]
157. Weiss DR, Ahn S, Sassano MF, Kleist A, Zhu X, Strachan R, Roth BL, Lefkowitz RJ, Shoichet BK. (2013) Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor. ACS Chem Biol, 8 (5): 1018-26. [PMID:23485065]
158. White CW, Choong YT, Short JL, Exintaris B, Malone DT, Allen AM, Evans RJ, Ventura S. (2013) Male contraception via simultaneous knockout of α1A-adrenoceptors and P2X1-purinoceptors in mice. Proc Natl Acad Sci U S A, 110 (51): 20825-30. [PMID:24297884]
159. Williams TJ, Blue DR, Daniels DV, Davis B, Elworthy T, Gever JR, Kava MS, Morgans D, Padilla F, Tassa S et al.. (1999) In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists. Br J Pharmacol, 127 (1): 252-8. [PMID:10369480]
160. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, Shenoy SK, Lefkowitz RJ. (2007) A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A, 104 (42): 16657-62. [PMID:17925438]
161. Xu X, Kaindl J, Clark MJ, Hübner H, Hirata K, Sunahara RK, Gmeiner P, Kobilka BK, Liu X. (2021) Binding pathway determines norepinephrine selectivity for the human β1AR over β2AR. Cell Res, 31 (5): 569-579. [PMID:33093660]
162. Yamashima T. (2003) Jokichi Takamine (1854-1922), the samurai chemist, and his work on adrenalin. J Med Biogr, 11 (2): 95-102. [PMID:12717538]
163. Yuan D, Liu Z, Kaindl J, Maeda S, Zhao J, Sun X, Xu J, Gmeiner P, Wang HW, Kobilka BK. (2020) Activation of the α2B adrenoceptor by the sedative sympatholytic dexmedetomidine. Nat Chem Biol, 16 (5): 507-512. [PMID:32152538]